Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Gate Neurosciences Inc
Mavalon Therapeutics Ltd (Ictive)
Noema Pharma AG
Taisho Pharmaceutical Holdings Co Ltd
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles
DT-011088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GATE-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOE-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-9881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TS-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0650786 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones
Featured News & Press Releases
Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease
Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The Intertiol Congress On Schizophrenia Research
Sep 02, 2007: Investigatiol Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in ture Medicine Finds
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Addex Therapeutics Ltd, 2021
Pipeline by Camino Pharma LLC, 2021
Pipeline by Denovo Biopharma LLC, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Gate Neurosciences Inc, 2021
Pipeline by Mavalon Therapeutics Ltd (Inactive), 2021
Pipeline by Noema Pharma AG, 2021
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021